Cardiovascular & hematological disorders drug targets最新文献_第9页

New Oral Anticoagulation after Heart Valve Replacement. 心脏瓣膜置换术后新的口服抗凝剂。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209111735

I. El-Battrawy, S. Baumann, A. Huseynov, I. Akin

引用次数: 1

Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management. 新型口服抗凝剂:对患者评估、治疗开始、随访和围手术期管理的建议。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209113125

S. Baumann, A. Huseynov, I. El-Battrawy, M. Renker, I. Akin

{"title":"Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management.","authors":"S. Baumann, A. Huseynov, I. El-Battrawy, M. Renker, I. Akin","doi":"10.2174/1871529X1502151209113125","DOIUrl":"https://doi.org/10.2174/1871529X1502151209113125","url":null,"abstract":"New oral anticoagulants (NOACs) are becoming available as alternatives to vitamin K antagonists (VKAs) to prevent systemic embolism in patients with non-valvular atrial fibrillation for the prevention and treatment of venous thromboembolism and pulmonary embolism. A comprehensive understanding of the basic concepts of hemostaseology, the underlying pharmacology, drug interactions and management of potential complications is essential for the selection of suitable patients to receive NOACs, for correct prescription and for optimal patient treatment. Furthermore, the use of NOACs in a perioperative setting is crucial, as it requires knowledge of time and dose of last intake of drug, current renal function and the planned procedure in order to assess the overall risk of bleeding. Although no antidote exists to reverse the effects of these novel drugs, selective substitution of coagulation factors and dialysis may be necessary. Therefore, choosing the most beneficial alternative to VKAs on an individual basis can be challenging for physicians. In conclusion, the recent introduction of NOACs represents an opportunity for anticoagulative treatment regimes, while the benefits, risks and limitations should be reflected carefully. The purpose of this systematic review is to highlight features and to provide practical guidance of NOACs in comparison with VKAs that should be considered in a multifaceted decision making process to improve efficacy and safety.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"1 1","pages":"120-6"},"PeriodicalIF":0.0,"publicationDate":"2015-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89937799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Novel Oral Anticoagulation--A Milestone in Anticoagulation History. 新型口服抗凝剂——抗凝史上的一个里程碑。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209124012

M. Yıldız, I. Akin

引用次数: 0

The Use of Novel Oral Anticoagulants in Atrial Fibrillation. 新型口服抗凝剂在房颤治疗中的应用。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209111019

U. Ansari, M. Behnes, C. Fastner, I. Akin

{"title":"The Use of Novel Oral Anticoagulants in Atrial Fibrillation.","authors":"U. Ansari, M. Behnes, C. Fastner, I. Akin","doi":"10.2174/1871529X1502151209111019","DOIUrl":"https://doi.org/10.2174/1871529X1502151209111019","url":null,"abstract":"Atrial fibrillation is known to be associated with an increased risk of ischaemic stroke and systemic embolism. After stratification using various risk calculation scores, patients were traditionally prescribed anticoagulants in the form of Aspirin or the traditional Vitamin K Antagonists. The use of Warfarin has proven to reduce incidents of ischaemic stroke; however its use has several limitations. The necessity for strict anticoagulation monitoring so as to maintain the narrow therapeutic range as measured by the international normalized ratio (INR) between 2 and 3 is one of these. In clinical practice, patients are within the therapeutic range lesser than two-thirds of the time and furthermore, its use is associated with a significant risk of major bleeding. The advent of Novel oral Anticoagulants marks a new era in anticoagulant therapy. The use of direct thrombin inhibitors and Factor Xa inhibitors has documented a favorable bleeding profile while being similarly or more efficacious when compared to VKA. Early studies indicate a significant reduction in the composite of stroke or systemic embolism and lowering of all-cause mortality. In this review we discuss the evidence for the clinical benefit and safety of the novel anticoagulants versus warfarin among patients with atrial fibrillation and probationary guidelines towards their use.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"22 1","pages":"97-100"},"PeriodicalIF":0.0,"publicationDate":"2015-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87328915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rationale for Development of New Oral Anticoagulants. 开发新型口服抗凝剂的基本原理。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209110044

M. Akin, J. Widder, I. Akin, M. Brehm, A. Schäfer

引用次数: 0

New Oral Anticoagulants in Coronary Artery Disease. 新型口服抗凝剂治疗冠状动脉疾病。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209111429

M. Behnes, C. Fastner, U. Ansari, I. Akin

引用次数: 4

Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis. 新型口服抗凝剂在静脉血栓栓塞治疗和血栓预防中的应用。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209110620

M. Akin, A. Schäfer, I. Akin, J. Widder, M. Brehm

{"title":"Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis.","authors":"M. Akin, A. Schäfer, I. Akin, J. Widder, M. Brehm","doi":"10.2174/1871529X1502151209110620","DOIUrl":"https://doi.org/10.2174/1871529X1502151209110620","url":null,"abstract":"Thrombo-embolism of the venous system consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE) is common and associated with high morbidity and mortality. Symptomatic venous thromboembolism (VTE) manifests in about 1/3 of cases as PE and 2/3 as DVT. There is a strongly compound between early mortality after venous VTE and PE, age, malignancies and cardiovascular diseases. Anticoagulation therapy is the main therapeutic approach for the treatment of acute VTE and to prevent recurrent VTE events. For decade's classic anticoagulants like heparin, low-molecular-weight heparins (LMWHs), fondaparinux, and vitamin K antagonists have been the gold standards in therapy and are widely used. Novel oral anticoagulants (NOAC) like the direct thrombin inhibitor (dabigatran etexilate) and the direct factor Xa inhibitors (e.g. rivaroxaban, apixaban, and edoxaban) have been introduced to overcome the drawbacks of vitamin K antagonists. The efficacy and safety of these NOAC have been investigated in several randomized trials. Here we want to give an overview about the NOACS in the treatment of acute and chronic VTE and their use for primary prevention of acute VTE.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"15 1","pages":"92-6"},"PeriodicalIF":0.0,"publicationDate":"2015-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75376850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Novel Oral Anticoagulation Laboratory Monitoring, Interaction and Treatment of Complications. 新型口服抗凝实验室监测、相互作用及并发症的治疗。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209112437

A. Huseynov, S. Baumann, I. El-Battrawy, I. Akin

引用次数: 0

Novel Oral Anticoagulation During Pulmonary Vein Isolation and Cardioversion. 新型口服抗凝剂在肺静脉隔离和心转复中的应用。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-01-01 DOI: 10.2174/1871529X1502151209112128

C. Fastner, M. Behnes, U. Ansari, I. Akin

引用次数: 0

Infective endocarditis. 感染性心内膜炎。

Cardiovascular & hematological disorders drug targets Pub Date : 2009-01-01 DOI: 10.1201/b15782-18

I. Starakis

引用次数: 0